Status:
UNKNOWN
Hybrid SPECT/CTCA for the Assessment of the Presence and Hemodynamic Significance of CAD in Asymptomatic Patients.
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Hodgkin Lymphoma Treated With Mediastinal Irradiation
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Mediastinal irradiation for treatment of malignancy increases the risk for coronary artery disease (CAD), while diabetes mellitus or other known risk factors can be absent at the time of the first cor...
Eligibility Criteria
Inclusion
- Asymptomatic HL patients without evidence of disease and without prior history of CAD that underwent mediastinal irradiation due to HL
Exclusion
- Known CAD (these patients will be excluded from the imaging study, but will be analyzed as separate control group)
- active HL or other active malignancy
- chronic renal failure
- pregnant/ nursing women
- previous allergic reaction to iodine contrast media
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01239446
Start Date
January 1 2011
Last Update
November 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Healthcare Campus
Haifa, Israel